HeartBeam, Inc. (BEAT) has seen a push of 12.20% in aftermarket following the announcement of a partnership with LIVMOR. However, the last trading session closed at $2.05 with a decrease of 5.96%.
Partnership of BEAT with LIVMOR – What’s up?
BEAT announced on 2nd February 2022 that it has entered into a partnership with LIVMOR. It is a digital health solutions firm that has partnered with BETA in order to create a HeartBeam-branded version of LIVMOR’s Halo+ FDA-cleared turnkey system for remote patient monitoring that connects doctors and patients. Moreover, the company will be able to reach the FDA submission deadline for the initial product. The product is an easy-to-use heart attack detection software solution for Emergency Department settings.
Furthermore, LIVMOR has successfully built a patient-engaged remote monitoring system of crucial physiological indicators, which BEAT believes may be converted to work with the Emergency Department software solution to improve MI detection accuracy. In addition, LIVMOR’s regulatory experience is a valuable asset to the company as the team pursues FDA authorization for the HeartBeam Platform. Lastly, the team is excited to collaborate with the LIVMOR on getting the software ready for FDA submission later this year.
Establishment of Scientific Advisory Board & Appointment of Michael Gibson
On 27th January 2022, BEAT reported that the company has established a Scientific Advisory Board and also appointed C. Michael Gibson as the Chairman of SAB. Dr. Gibson brings almost 3 decades of expertise in cardiology as a scientist. The company welcomes Mr. Gibson on account of the Board executives team.
He is a valuable asset for BEAT because his scientific expertise will be invaluable in advancing the product development, which will include an ER solution for more accurate MI diagnosis and a comprehensive telehealth system for remote MI monitoring.
Appointment of Chief Operating Officer by BEAT – Worth it?
BEAT announced on 22nd December 2021 that Alan Baumel has been appointed as the Chief Operating Officer. Mr. Baumel has a background of product development, production, quality assurance, and regulatory affairs specialist with over 35 years of experience.
BEAT is happy to be welcome Alan to the Company on behalf of the board of directors. Furthermore, Alan’s vast experience and industry understanding will be critical in hastening industrialization and FDA product development. Alan’s extensive experience, particularly with cardiac devices, makes him a perfect fit for the heart attack detection and monitoring system. Last but not the least, Alan will not only strengthen the fundamental management team but will also help the team to commercialize and scale the technology.
